Abstract
BACKGROUND The prescribing of adjuvant chemotherapy for patients with breast cancer must balance the survival benefit against treatment-related toxicities. TAILORx, a phase 3 randomized clinical trial, demonstrated that endocrine therapy alone was, on average, noninferior to chemoendocrine therapy for patients classified as intermediate risk by a 21-gene Recurrence Score (RS) assay. Uncertainty remains about the optimal strategy to identify which intermediate-RS individuals derive benefit from chemotherapy.
METHODS We analyzed 6735 patients from the TAILORx trial using Ataraxis Breast CTX with pathology images (H&E slides) and RS available. CTX is an AI model which integrates morphologic features extracted from H&E-stained slides with clinical variables to generate individualized predictions of prognosis (CTX-prognostic) and chemotherapy benefit (CTX-benefit). No data from TAILORx were used to train CTX and CTX was not retrained or recalibrated for this study. Analyses were prespecified in a protocol approved by ECOG-ACRIN.
RESULTS Among patients treated with endocrine therapy alone, CTX-prognostic predicted disease-free interval (DFI), with a hazard ratio per 1 SD increase of 1.651 (95% CI, 1.511-1.803, p < 0.001) and C-index of 0.736 (95% CI, 0.697-0.770). Performance was similar in patients treated with chemoendocrine therapy (hazard ratio = 1.642 [95% CI, 1.495-1.804, p < 0.001], C-index = 0.720 [95% CI, 0.681-0.756]). After adjusting for the RS, CTX-prognostic remained significantly associated with DFI in both treatment groups. In the intermediate-RS subgroup, the treatment-by-biomarker interaction for CTX-benefit was significant (p = 0.016), with patients identified as high-benefit deriving a 5.6% increase in observed 5-year DFI rates from the addition of chemotherapy, compared with no detectable benefit in low-benefit patients. Stratifying the same subgroup by RS at a threshold selecting a similar proportion of patients yielded no significant interaction (p = 0.20).
CONCLUSIONS In an analysis of TAILORx, CTX-prognostic stratified patients according to their risk of recurrence. Among intermediate-RS patients, CTX-benefit identified who derived clinically meaningful benefit from adjuvant chemotherapy, a population currently not identifiable by the RS alone.
Competing Interest Statement
CT, DB, JP, KZ, JC, CL, AM, JB, LB, BM, JW, and KJG are equity holders of Ataraxis AI. All other authors declare no competing interests.
Clinical Trial
NCT00310180
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The TAILORx trial was conducted in accordance with the Declaration of Helsinki, the Belmont Report, and the U.S. Common Rule (45 CFR 46), and all participants provided written informed consent at enrollment. The present secondary analysis used retrospective, deidentified data and received approval from the WCG Institutional Review Board with a waiver of informed consent under 45 CFR 46.116(f). Data were obtained under an approved data access request and executed Data Use Certification from ECOG-ACRIN.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
The name of the author "Cerise Tang" has been corrected from "Ceris Tang". The corresponding author has been changed from Joseph A. Sparano to Nancy Chan. The ethics statement in the PDF has been changed to be more specific.
Data Availability
The data is not publicly available due to institutional and ethical constraints. Access to data from the TAILORx trial can be requested directly from ECOG-ACRIN.
Funder Information Declared
